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The metalloid selenium is required in the
form of selenocysteine in several mammalian
enzymes with roles in defense against reactive
oxygen species (ROS). These include isoforms
of thioredoxin reductase (TrxR), glutathione
peroxidase (Gpx), and a selenium-dependent
form of methionine sulfoxide reductase (SelR)
(Arner and Holmgren 2000; Kryukov et al.
2002; Stadtman 2000; Tamura and Stadtman
1996). Selenocysteine is inserted via transla-
tion of a UGA codon, normally a stop codon,
in a process that is well described in
Escherichia coli and is currently being charac-
terized in mammalian systems (Berry et al.
2001, 2002; de Jesus et al. 2006; Small-
Howard et al. 2006). When selenium levels
are reduced in the diet, selenoenzyme activi-
ties are similarly reduced (Hill et al. 1997; Lei
et al. 1995). Selenium deficiency has been
shown to result in dramatic increases in ROS
with concomitant cell death (Saito et al.
2003). This cell death can be prevented by
administration of vitamin E and other anti-
oxidants, demonstrating that the primary need
for selenium in a mammalian cell, at least in
culture, is related to its role in enzymes
involved in defense against ROS.
Thioredoxin reductase (TrxR), which cata-
lyzes the NADPH-dependent reduction of
oxidized thioredoxin, was ﬁrst identiﬁed as a
selenoprotein in 1996 by Tamura and
Stadtman (Tamura and Stadtman 1996).
Cellular glutathione peroxidase (cGpx), which
catalyzes the glutathione-dependent reduction
of hydroperoxides to their corresponding alco-
hol, was the first mammalian selenoprotein
identiﬁed (Flohe et al. 1973). Several isoforms
of Gpx with varying substrate speciﬁcity and
expression patterns in different tissues have
been identiﬁed (Brigelius-Flohe 1999). cGpx
acts primarily on hydrogen peroxide, whereas
phosphohydrolipid Gpx (PHGpx) has a
broader specificity for cholesterol and phos-
pholipid hydroperoxides. PHGpx also plays a
critical role in reproduction and has been
shown to regulate the activity of lipoxygenases
(Straif et al. 2000; Ursini et al. 1999; Werz
and Steinhilber 1996). As many as six isoforms
of Gpx and four isoforms of TrxR have been
uncovered in a recent in silico analysis of the
completed human genome (Kryukov et al.
2003).
In stark contrast to selenium, exposure to
the metalloid arsenic has been strongly linked
to the development of cancer of the bladder,
liver, lung, kidney, and skin, with skin as the
primary target (Kitchin 2001). Exposure to
elevated concentrations of arsenic is a public
health crisis in areas of Bangladesh, Taiwan,
and China. Although well established as a
carcinogen, the mechanism of arsenic-
induced carcinogenesis is not well deﬁned at
the molecular level. Many recent studies
using cell culture model systems have demon-
strated an increase in oxidative stress upon
exposure to arsenicals (Kitchin and Ahmad
2003). Global gene expression analysis of pri-
mary keratinocytes treated with arsenite
demonstrated a sustained upregulation of
hemeoxygenase mRNA, a classic marker of
oxidative stress (Rea et al. 2003). Arsenite was
found to be more potent than the pentavalent
arsenate in the induction of oxidative stress
(Rea et al. 2003). The mRNA level of the
selenoenzyme thioredoxin reductase was also
increased up to 13-fold under these condi-
tions; however, enzyme activities or protein
levels of TrxR1 were not analyzed. Another
study, also monitoring global gene expression
in keratinocytes treated with arsenite, revealed
increases in mRNA encoding thioredoxin and
TrxR1 (Hamadeh et al. 2002). These studies
assert that increased ROS generated upon
long-term exposure to arsenic is the primary
mechanism behind the increased rates of can-
cer in populations with elevated arsenic expo-
sure. Although oxidative stress has been
reported in several cases (Hamadeh et al.
2002; Kitchin and Ahmad 2003; Lee et al.
2004; Liao et al. 2004; Pi et al. 2003;
Schwerdtle et al. 2003; Trouba et al. 2002),
the mechanism for the increase in reactive
oxygen species has yet to be elucidated.
Moxon first uncovered an interaction of
arsenic and selenium in studies on the toxicity
of selenium from seleniforous grains (Moxon
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BACKGROUND: Exposure to arsenic has been associated with development of skin, lung, bladder, liver,
and kidney cancer. Recent evidence suggests that an increase in oxidative stress in cells treated with
arsenicals represents the molecular mechanism behind arsenic-induced carcinogenesis. Selenium, in
the form of selenocysteine, is necessary for the activity of several enzymes with a role in defense
against reactive oxygen species. A mutual sparing effect between arsenic and selenium has been shown
in animal studies when both metalloids are present in high concentrations. 
OBJECTIVES: To determine whether changes in selenoprotein synthesis may be an underlying mecha-
nism behind arsenic-induced carcinogenesis, we analyzed the new synthesis of selenoproteins within
cells after exposure to inorganic or methylated arsenicals using a human keratinocyte cell model. 
RESULTS: Addition of arsenite to culture medium blocked new synthesis of selenoproteins when
selenium was present in the form of selenite, and appeared to stimulate the use of serum-derived
selenium. Monomethylarsonous acid (MMAIII) treatment of cells, in contrast, did not block all new
synthesis of selenoproteins but did result in an increase in cytosolic thioredoxin reductase (TrxR1)
at both the mRNA and protein levels. MMAIII also reduced the new synthesis of cellular glutatione
peroxidase (cGpx) and other smaller selenoproteins. Dimethylarsinous acid (DMAIII) stimulated
selenoprotein synthesis by an as yet unknown mechanism. 
CONCLUSIONS: These results suggest that arsenite and MMAIII are key metabolites that trigger
higher levels of TrxR1, and both lead to a reduction in the expression of cGpx. Together these
effects certainly could lead to carcinogenesis given the knowledge that many cancers have higher
levels of TrxR, and reduced Gpx levels will reduce the cell’s ability to defend against reactive oxygen
species. Based on these results, the impact of the trivalent arsenicals arsenite and MMAIII on seleno-
protein synthesis may indeed represent a potential molecular mechanism for the higher rates of can-
cer observed in populations exposed to high levels of arsenic.
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that a “mutual sparing effect” can be demon-
strated when animals or cells in culture are
treated with arsenic and selenium (Levander
1977; Styblo and Thomas 2001). A key paper
published in 2000 (Gailer et al. 2000) identi-
ﬁed seleno-bis(S-glutathionyl) arsinium ion as
the major excretion product in rabbits admin-
istered arsenite and selenite. This likely uncov-
ered the primary molecular mechanism
behind the Moxon effect—which only relates
to the co-administration of inorganic forms of
arsenic and selenium. The direct analysis of
the impact of arsenite and/or downstream
methylated arsenic species on selenoprotein
synthesis in either animal studies or tissue
culture models has yet to be studied.
Although early toxicology studies ignored
the potency of methylated forms of arsenic
(Hirano et al. 2004; Kitchin and Ahmad
2003; Schwerdtle et al. 2003; Thomas et al.
2004), the available synthesis of trivalent
forms of monomethylarsonous acid (MMAIII)
and dimethylarsinous acid (DMAIII) now
allows study of these compounds in cell cul-
ture model systems (Styblo et al. 2000).
Indeed, these methylated forms have been
shown to be more cytotoxic than inorganic
arsenite and arsenate. The impact of these
methylated arsenicals on the promotion of
cancer is still poorly understood, and their
potential interaction with selenium com-
pounds has not been studied.
In this article we discuss the effects of
inorganic and methylated trivalent arsenicals
on selenoprotein synthesis using a kera-
tinocyte cell model. This study was under-
taken to determine the overall impact of
arsenicals on selenoprotein synthesis.
Materials and Methods
Materials. Sodium selenite and sodium arsenite
were purchased from Acros Organics
(Geel, Belgium). MMAIII and DMAIII were
obtained from W. Cullen, Department of
Chemistry, University of British Columbia
(Vancouver, Canada). 75Se radioisotope, in
the form of selenite, was obtained from the
University of Missouri Research Reactor
(MURR, Columbia, MO). 35S-Methionine/
cysteine labeling mix was from Amersham
BioSciences (Piscataway, NJ). 
Cell culture. We cultured HaCat cells as a
monolayer in Dulbecco’s modification of
Eagle’s medium (DMEM) with L-glutamine,
sodium pyruvate, and 4.5 g/L glucose supple-
mented with 10% fetal bovine serum (FBS),
100 µg/mL streptomycin, and 100 IU/mL
penicillin (Mediatech, Herndon, VA). The
cultures were incubated at 37°C with a
humidiﬁed 5% carbon dioxide atmosphere to
maintain proper pH. For cultivation in
deﬁned medium, cells were transitioned from
DMEM to defined keratinocyte medium
(DKM; Invitrogen, Carlsbad, CA) in 25%
stepwise increments (e.g., 75% DMEM, 25%
DKM first passage, 50% DMEM, 50%
DKM second passage, and so forth). This
conditioning allowed for optimal growth of
the culture once growing in DKM without
serum, as direct transition to DKM resulted
in altered cell morphology and cell death.
We obtained the African green monkey
kidney cell line, COS7, from the American
Type Culture Collection (Manassas, VA).
This cell line was used for reporter gene
fusion assays, as the promoter for these con-
structs are driven by SV40 virus (Handy et al.
2005). COS7 were cultivated in DMEM sup-
plemented with 10% FBS. 
Cell viability assay. To determine cyto-
toxicity of arsenicals, we cultured HaCat cells
in 96-well dishes with approximately 2,500
cells per well. After one day of growth to
allow for development of a healthy monolayer
(70–80% conﬂuent), arsenicals were added at
varying concentrations and the cells were
incubated for 24 hr. A tetrazolium dye,
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) was added
(1.2 mM) and cells were subsequently incu-
bated at 37°C with 5% CO2 in the dark for
4 hr. To solubilize the dye, we added 100 µL
cell lysis solution (10% SDS, 5 mM HCl) to
each well and incubated the plate overnight at
37°C . Absorbance of the soluble dye was
determined at 570 nm in a Opsys MR
microplate reader (Dynex Technologies,
Chantilly, VA). We used a standard curve of
known concentrations of cells (determined by
direct cell counting using trypan blue in a
haemocytometer) to validate the use of this
assay as a representative measure of cell viabil-
ity in this cell line.
Radioisotope labeling of selenoproteins.
The incorporation of selenium into seleno-
proteins was monitored by labeling HaCat
cells using 75Se in the form of selenite
(University of Missouri). Unlabeled sodium
selenite was added to a ﬁnal concentration of
10 nM, and approximately 2 µCi of radioiso-
tope was added to each culture (cultivated in
6-well cell culture dish). Under these growth
conditions, only selenoproteins containing
selenium in the form of selenocysteine are
labeled. For analysis of general protein syn-
thesis, we added 30 µCi of 35S in the form of
methionine and cysteine (Redivue Pro-Mix
35S, Amersham BioSciences, San Francisco,
CA) to HaCat cells in DMEM (low cysteine/
methionine) with 10% FBS. 
We harvested HaCat cells by treating the
cells with 0.05% EDTA in Dulbecco’s phos-
phate-buffered saline (DPBS) without cal-
cium/magnesium for 15 min. This EDTA
solution was removed and replaced with
trypsin–EDTA and further incubated at 37°C
for 5 min. Cells released by treatment with
trypsin were then isolated by centrifugation
(500 × g), washed in PBS, and subsequently
resuspended in 0.1 mL cell lysis buffer
[50 mM tricine (pH 8.0), 0.1 mM benzami-
dine, 0.5 mM EDTA, and 1 mM DTT].
Cells were lysed by sonication for 5 sec using
a Model 100 sonic dismembrator (Thermo
Fisher Scientific, Pittsburgh, PA) at a power
setting of 4 W. The resulting crude cell lysate
was clariﬁed by centrifugation at 13,000 × g
for 5 min at 4°C. 75Se in cell extracts was
detected using a Wallac Wizard Gamma
Counter, Model 1470 (PerkinElmer,
Wellesly, MA). 35S-labeled proteins in cell
extracts were determined by liquid scintilla-
tion using a Packard TriCarb 2900TR
counter (PerkinElmer). Protein concentration
was determined by the method of Bradford
using bovine serum albumin as a standard
(Bradford 1976).
For radiolabeling of COS7, cells were
seeded in 6-well tissue culture dishes in
0.5 mL DMEM with 10% FBS and culti-
vated for 24 hr at 37°C with 5% CO2. Cells
were labeled with radioactive 75Se (2.5 µCi)
and simultaneously treated with 0, 2, or 6 µM
sodium arsenite. Once these compounds were
added to the culture medium, cells were incu-
bated for an additional 24 hr at 37°C with
5% CO2 before harvesting as described
above, omitting the EDTA treatment prior to
addition of trypsin. 
Immunoblot analysis of TrxR1 and cGpx.
Polyclonal rabbit serum raised against the
N-terminal peptide of human TrxR1 were a
gift from T.C. Stadtman (National Heart,
Lung, and Blood Institute/National Institutes
of Health, Bethesda, MD). We obtained poly-
clonal sheep antibodies to cGpx from
GeneTex, Inc. (San Antonio, TX). We treated
HaCat cells with arsenite or MMAIII for
24 hr, then harvested the cells by treatment
with trypsin as described above. Clariﬁed cell
extracts of HaCat cells (obtained after sonica-
tion as described above) were separated by
SDS-PAGE (15%), subsequently transferred
to polyvinylidene diflouride (PVDF) mem-
brane, and blocked with Tris-buffered saline-
Tween (0.2% Tween) containing 4% dry
milk for 1 hr at 25°C. We incubated mem-
branes with primary serum at 4°C for 16 hr at
a dilution of 1:1000 in blocking buffer. After
washing with TBS–Tween, we incubated the
membrane with the appropriate secondary
antibody conjugated with alkaline phosphatase
at 25°C for 1 hr. The blot was developed
using CDP-star chemiluminescent substrate
(Applied Biosystems, Bedford, MA) and
visualized on X-ray ﬁlm.
Real-time reverse transcriptase–polymerase
chain reaction (RT-PCR) analysis of seleno-
protein gene expression. We treated HaCat
cells with arsenite or MMAIII for 24 hr, then
harvested the cells by treating with trypsin as
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washed with diethylpyrocarbonate (DEPC)-
treated PBS. Total RNA was isolated using
the ChargeSwitch Total RNA Cell kit
(Invitrogen) and quantified by ultraviolet
(UV)-visible spectrophotometry at 260 nm
using an Agilent 8453 UV-Visible spectro-
photometer (Agilent Technologies, Santa
Clara, CA). Puriﬁed RNA (0.5 µg) was used
as a template for the generation of cDNA
using the iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA). 
We performed real-time PCR amplifica-
tion using the Bio-Rad i-Cycler (BioRad).
Primer pairs used for analysis (forward, then
reverse) were cGpx: 5´-GGGACTACACC
CAGATGAA CG-3´ and 5´-CAAGGTG
TTCCTCCCT CGTAG-3´; TrxR1: 5´-
AGCTCAGT CCACCAATAGTGA-3´ and
5´-GGTATTT TTCCAGTCTTTTCAT-3´;
β-actin: 5´-CATGTACGTTGCTATCCA
GGC-3´ and 5´-CTCCTTAATGTCACGCA
CGAT-3´. The level of transcripts for β-actin
was used as an internal standard. BioRad iQ
SYBR green supermix (Bio-Rad) was used for
real-time PCR amplification with oligonu-
cleotides at a concentration of 200 nM each.
cDNA was diluted 1:100 before addition to
the reaction mix. Reaction conditions (for
β-actin and TrxR1 analysis) consisted of a sin-
gle cycle at 95.0°C for 3 min; subsequent
40 cycles of 95.0°C for 10 sec, 55.0°C for
45 sec. For reactions using cGpx-specific
primers the amplification was as follows: a
single cycle at 94.0°C for 3 min; subsequent
40 cycles of 94.0°C for 30 sec, 55.0°C for
30 sec, and 70.0°C for 30 sec. Melt curve
analysis was performed to conﬁrm the presence
of a single product. We calculated the effi-
ciency of amplification for each target gene
using a 10-fold dilution series of control
cDNA. Relative expression of mRNA levels for
TrxR1 and cGpx was calculated according to
the Pfafﬂ method (Pfafﬂ 2001).
Reporter gene fusion assays. A reporter
gene fusion (UGA hSECIS S) previously
described (Handy et al. 2005) was generously
provided by D. Handy (Boston University
School of Medicine, Boston, MA). COS7
cells were seeded at 80,000 cells per well in
24-well tissue culture plates in 1 mL DMEM
with 10% FBS. After 24-hr incubation, cells
were transfected with 250 ng luciferase
(hSECIS) plasmid and 10 ng control Renilla
plasmid (pRL-CMV; Promega, Madison,
WI). Plasmids were pretreated with Plus
reagent (Invitrogen). Lipofectamine 2000 was
used for transfection of DNA in 200 µL
Opti-Pro medium (Invitrogen). Cells were
incubated with liposomes for 3 hr. DMEM
supplemented with either 0.1 or 10% FBS
(800 µL) was added, and the cells were subse-
quently treated with sodium selenite (10 or
50 nM) or 4 µM sodium arsenite for 24 hr.
Transfection media was then removed and
cells were cultivated for an additional 24 hr in
DMEM with 0.1 or 10% FBS. After incuba-
tion, media was removed and cells were lysed
in detergent lysis buffer supplied by the Dual-
Luciferase Reporter Assay System (Promega).
Luminescence was quantified as a ratio of
Fireﬂy luciferase/ Renilla luciferase activity in
cell extracts using an LMax luminometer
(Molecular Devices, Sunnyvale, CA).
Results
Cytotoxicity of arsenicals in HaCat cells.
Before assessing the effects of arsenicals on sele-
nium incorporation, we assessed the cyto-
toxicity of these compounds in HaCaT
cultured in DMEM with serum (10%) using
the MTT assay (Ohno and Abe 1991). These
results are summarized in Figure 1. Pentavalent
arsenicals were the least cytotoxic among the
compounds tested. We observed a 50%
reduction in cell viability when 375 µM arse-
nate was added to the culture medium. This
is far from physiologically relevant concentra-
tions of arsenicals, generally considered to be
low micromolar or nanomolar levels when
tested in cell culture systems to represent an
environmental exposure (Hughes 2002).
Similarly, cacodylic acid (dimethylarsinic acid
- pentavalent) was not cytotoxic at levels
< 400 µM (data not shown). It should be
noted that lower concentrations (< 70 µM of
arsenate) actually stimulated metabolism as
determined by reduction of MTT dye. This
was indeed the case for each arsenical tested,
although this apparent proliferative effect was
seen at far lower concentrations with other
compounds (Figure 1). 
In contrast to pentavalent compounds,
trivalent arsenicals were far more cytotoxic.
Arsenite reduced cell viability nearly 50% at
22 µM. MMAIII, a trivalent methylated
arsenical, was the most cytotoxic compound in
this cell line with a 50% decrease in viability at
4 µM. DMAIII was less cytotoxic and resem-
bled arsenite in the reduction of cell viability.
These experiments were designed to determine
the level of arsenical that does not signiﬁcantly
affect cell viability in 24 hr. These data guided
our design of experiments to follow selenium
incorporation using radiolabeled 75Se. The
toxicity of these compounds has been reported
previously, and our results are comparable to
those seen in cell lines (primary keratinocytes)
other than HaCat (Styblo et al. 2000).
Selenium radioisotope studies to follow
selenoenzyme synthesis in undefined media.
To determine the impact trivalent arsenicals
have on selenoprotein synthesis, we treated
HaCat cells with several concentrations of
each arsenical while introducing radiolabeled
selenium (75Se) in the form of selenite to the
culture medium. For this analysis, cells were
treated with concentrations of arsenicals that
did not significantly reduce cell viability
(< 50%) within 24 hr. 
In control cells, the predominant seleno-
protein bands corresponded with the expected
Ganyc et al.
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Figure 1. Cytotoxicity of trivalent arsenicals in HaCat cells cultured in DMEM containing 10% serum. HaCat
cells were cultivated in the presence of arsenicals at concentrations indicated in each plot, noting that the
scale is not identical. MTT dye reduction was assessed after incubating cells with arsenicals for 24 hr, and
the absorbance obtained was compared with untreated cells to determine the relative percent cell viability.
Data represent the mean of several experiments (minimum of three replicates) and the SD is plotted as error.
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C Dmolecular weight of TrxR1 (59 kDa) and
cGpx, 22 kDa based on a molecular weight
standard. This identification was confirmed
with immunoblots (data not shown). Several
potential isoforms of TrxR appear to be pre-
sent, supported by in silico analysis that
revealed several genes encoding TrxR-like
enzymes (Kryukov et al. 2003). Other smaller
selenoproteins are also present in HaCat and
could be one of many small selenoproteins
identified in the aforementioned genome
analysis (Kryukov et al. 2003).
When cells were treated with arsenite, we
observed a clear concentration-dependent
decrease in selenium incorporation into
selenoproteins (Figure 2). The effect seems to
be general inhibition as all the selenoproteins
appear to decrease in parallel in the presence
of increasing concentrations of arsenite. In
contrast, cells treated with similar concentra-
tions of arsenate (pentavalent) showed no sig-
nificant changes. Treatment with similar
concentrations of cacodylic acid also had no
effect on selenoprotein synthesis (data not
shown), and thus pentavalent compounds
were not further tested. 
In contrast to arsenite, treatment with low
micromolar levels of MMAIII revealed a differ-
ential effect for incorporation of selenium. The
level of radiolabeled TrxR1 increased, whereas
selenium incorporation into cGpx and other
small selenoproteins decreased. The differential
effect of MMAIII on selenoprotein synthesis is
certainly an intriguing result. Together these
results show that MMAIII affected selenium
metabolism in a fundamentally different man-
ner than arsenite, demonstrating that each
trivalent arsenical has a specific effect.
Incubation of cells with DMAIII led to an
increase in selenium incorporation into all
selenoproteins at 4 µM, but this trend was
reversed at higher concentrations (Figure 2).
Similar experiments with cells harvested at later
time points (e.g., 48 hr after addition of arsen-
ite and radiolabeled selenium) exhibited similar
results (data not shown), indicating that the
keratinocytes cannot recover their ability to
incorporate selenium into selenoproteins after
brief adaptation to the arsenic exposure. 
Arsenite does not inhibit general protein
synthesis. To conﬁrm that this inhibition was
not simply due to a general inhibition of pro-
tein synthesis, we tested the incorporation of
35S-methionine/cysteine in the presence of
varying concentrations of sodium arsenite.
Although there was a slight increase in pro-
tein synthesis in the presence of low arsenite
(200 nM), general protein synthesis was not
significantly inhibited by arsenite (data not
shown). It is possible that at low concentra-
tions, arsenite (and other arsenicals) induces a
proliferative effect on cells by increasing gen-
eral protein synthesis. A recent study has also
observed a similar proliferative effect in
keratinocytes treated with these arsenicals
(Mudipalli et al. 2005).
Effect of arsenite is not cell-line specific.
We examined the effect of treatment of other
cell lines with arsenite to confirm that the
inhibitory effect of arsenite was not isolated to
one cell type. The well-studied epithelial cell
line HeLa S3 and the mouse cell line
NIH3T3 were chosen for these experiments.
Addition of increasing concentrations of
arsenite to either cell line in the presence of
radiolabeled selenium also demonstrated a
similar decrease in the incorporation of sele-
nium into selenoproteins (data not shown).
Thus, the apparent inhibition of selenium
incorporation under these culture conditions
appeared to be a general phenomenon for
cells in culture. Because of the differential and
pronounced effects of arsenite and MMAIII
on selenoprotein synthesis, we further probed
the effects of these compounds on expression
of the genes encoding selenoenzymes in the
HaCat model system.
Treatment with arsenite or MMAIII
increases mRNA levels encoding TrxR1. Using
real time RT-PCR we observed significantly
higher levels of mRNA encoding TrxR1 upon
treatment of cells with 2 or 6 µM arsenite
(Figure 3A). In contrast, the level of cGpx
mRNA was reduced by 80% compared with
control cells when cultured with 6 µM arsen-
ite. The reduction in cGpx mRNA was also
concentration dependent (Figure 3B).
MMAIII also slightly reduced the levels of
mRNA encoding cGpx, and led to a similar
increase in mRNA encoding TrxR1, yet in
both cases the changes were not as dramatic.
These results are in line with the selenium
incorporation data from Figure 2 for MMAIII
treatment—increases in TrxR1 levels and
decreases in cGpx. However, for arsenite
treatment, the results of real time RT-PCR
analysis did not parallel the results shown in
Figure 2. This suggests that arsenite treatment
may somehow trigger the use of nonlabeled
selenium present in the culture medium
Impact of arsenicals on selenoprotein synthesis
Environmental Health Perspectives • VOLUME 115 | NUMBER 3 | March 2007 349
Figure 2. Effect of arsenicals on incorporation of selenium into selenoproteins in DMEM containing 10%
serum. HaCat cells were cultivated in the presence of 75Se–selenite (10 nM) and treated with sodium
arsenite, sodium arsenate, MMAIII, or DMAIII at the concentrations indicated. Cells were harvested after
24-hr incubation with arsenicals and radioisotope selenium. Twenty-ﬁve micrograms of protein from crude
cell extract were separated by 15% SDS-PAGE. Selenoproteins were identiﬁed by autoradiography using
standard protein markers (molecular weight indicated at left of autoradiogram) based on Coommassie-
stained gels before exposure. 
Arsenite Arsenate MMAIII DMAIII
026 1 0 1 1 0 51 2 3 1 4 7
Arsenical (μM)
TrxR1
cGpx
Figure 3. Treatment of HaCat with trivalent arsenicals results in increased expression of TrxR1 (A) and
decreased expression of cGpx (B) when cells are treated in medium containing serum. Real-time RT-PCR
analysis was used to determine the relative mRNA levels of transcripts encoding TrxR1 and cGpx. Fold
induction is plotted versus control cultures (no arsenical addition). β-Actin levels were used as an internal
control for quantitative RT-PCR analysis. See ”Materials and Methods” for details. Error bars represent
mean ± SD for at least three independent RNA samples isolated from independent cultures.
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TrxR1 and cGpx protein levels to probe
whether the apparent increase or decrease in
mRNA encoding these enzymes also affected
protein levels.
Effect of trivalent arsenicals on TrxR1
and cGpx protein levels. Using antibodies spe-
cific for an N-terminal peptide of human
TrxR1, we determined the amount of TrxR1
protein in cytosolic extracts after treatment of
cells with MMAIII or arsenite for 24 hr.
Figure 4 clearly shows that treatment with
arsenite or MMAIII resulted in significant
increases in TrxR1. Densitometry revealed a
50% increase in TrxR1 levels treated with
6 µM arsenite and a nearly 2-fold increase in
TrxR1 levels in cells treated with either 1 or
3 µM MMAIII. The amount of cGpx protein
decreased under the same conditions (nearly
50% in arsenite-treated cells, based on densit-
ometry), confirming that the impact of
arsenicals on mRNA levels is correlated to the
amount of these proteins produced. These
results also show selenoproteins are still being
produced in cells treated with arsenite or
MMAIII. Because the isotope labeling uses
selenite, the uptake and metabolism of sele-
nium sources other than selenite (serum-
derived selenium sources) are apparently
induced upon treatment with arsenite. 
Effects of trivalent arsenicals on seleno-
protein synthesis in a serum-free deﬁned cul-
ture medium. Uptake of either inorganic
selenium or selenium derived for serum is
poorly understood. Since selenoprotein P and
a small molecule form of selenium, as yet
unidentified, are present in FBS (Burk and
Hill 2005), we determined the impact of
arsenicals on selenoprotein synthesis in the
absence of serum. We transitioned HaCat cells
from DMEM with serum to a deﬁned culture
medium for keratinocytes (DKM, Invitrogen).
This was carried out in a step-wise manner
(see “Materials and Methods”). Once transi-
tioned, cells grew at a slightly slower rate in
DKM, but cell morphology was consistent
with cells cultured with serum.
Before evaluating the impact of arsenicals
on selenoprotein synthesis, the cytotoxicity of
arsenicals was tested under these culture con-
ditions. The cytotoxicity of arsenate and
arsenite was similar to that seen in undeﬁned
media (data not shown), but MMAIII was
slightly more cytotoxic. Even more toxic was
DMAIII, with a reduction of cell viability of
50% at approximately 7.5 µM. This was in
contrast to very weak cytotoxicity of DMAIII
in cells cultured with serum (Figure 1). This
suggests that DMAIII may be interacting with
components of serum, although this has yet
to be tested directly.
Although the cytotoxicity was somewhat
increased under these culture conditions, we
analyzed selenoprotein synthesis by radio-
isotope labeling using the same conditions as
in Figure 2 to enable a direct comparison. In
contrast to the inhibition seen in Figure 2,
arsenite actually stimulated the incorporation
of radioisotope selenium into selenoproteins
when arsenite was present at 2 and 6 µM in
the culture medium. A higher concentration
(10 µM) did result in an inhibitory effect,
however, mimicking the inhibitory action of
arsenite seen in Figure 2. Arsenate decreased
slightly the level of radioisotope-labeled pro-
tein. The effects of both MMAIII and DMAIII
on selenium incorporation were consistent
with those seen in undefined medium
(Figures 2 and 5). Clearly the greatest change
in selenium labeling in DKM occurred upon
treatment with arsenite.
Treatment with arsenite or MMAIII in
DKM results in induction of TrxR1 and
decreases in cGpx expression. Again using real
time RT-PCR, we analyzed the levels or
mRNA encoding TrxR1 and cGpx in cells
treated with MMAIII or arsenite but with cells
cultured in DKM. As in undeﬁned medium,
the level of TrxR1 mRNA increased signifi-
cantly, with an even more pronounced effect
Ganyc et al.
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Figure 4. Measurement of TrxR1 and cGpx levels in cells treated with arsenite and MMAIII. Immunoblot
analysis of TrxR1, cGpx, and β-actin from cytosolic extracts of cells treated with arsenite and MMAIII).
Cytosolic proteins isolated from cells cultured in DMEM and 10% FBS and treated with arsenicals at the
concentrations indicated were separated on a 4–20% SDS-PAGE gel, transferred to PVDF, and probed
using polyclonal antibodies to TrxR1, cGpx, or β-actin. Immunoreactive bands were confirmed to cor-
respond to radiolabeled proteins using authentic mouse liver TrxR1 and cGpx (data not shown).
Arsenite (μM) MMAIII (μM)
TrxR1
cGpx
β-Actin
Control 2 6 1 3
Figure 5. Impact of arsenicals on selenoprotein synthesis in HaCat cultured in defined keratinocyte
medium (DKM). HaCat cells were cultivated in the presence of 75Se-selenite (10 nM) as in Figure 2 with the
exception of being cultivated in DKM. Twenty-five micrograms of protein from crude cell extracts were
separated by 15% SDS-PAGE. 
Arsenite Arsenate MMAIII DMAIII
026 1 01 1 0 51 2 3 1 4 7
Arsenical (μM)
TrxR1
cGpx
Figure 6. Treatment of HaCat with trivalent arsenicals results in increased expression of TrxR1 (A) and
decreased levels of cGpx (B) mRNA when cultured in DKM. Real-time RT-PCR analysis was used to deter-
mine the relative mRNA levels of transcripts encoding TrxR1 and cGpx as in Figure 3. Error bars represent
mean ± SD for at least three independent RNA samples isolated from independent cultures.
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increase in the level of mRNA encoding
TrxR1 also appears to be concentration
dependent with respect to the arsenical added
to the culture medium (Figure 6A). Similar
treatment with trivalent arsenicals also resulted
in signiﬁcant decreases in cGpx mRNA levels
(Figure 6B). This indicates that the impact of
trivalent arsenicals on mRNA levels encoding
these two selenoenzymes is not affected by the
presence or absence of serum. 
Total selenoprotein synthesis is inhibited in
cells treated with MMAIII or arsenite in DKM.
Given that the levels of mRNA for TrxR1 are
increased, we determined whether a signiﬁcant
increase in TrxR1 protein occurred using
immunoblots. Indeed, Figure 7 clearly shows
that the level of TrxR1 does not signiﬁcantly
decrease in cells treated with either arsenite or
MMAIII. However, cGpx levels do appear to
be decreasing signiﬁcantly (as much as 50% in
cells treated with 3 µM MMAIII based on den-
sitometry). This would imply that even in the
presence of more abundant TrxR1 mRNA, the
level of selenoprotein synthesis is stymied by
these trivalent arsenicals in cells grown in the
absence of serum. The decrease in cGpx is
likely due to a more rapid rate of turnover rela-
tive to TrxR1, but this has yet to be shown.
Nonetheless, these data strongly suggest that
either MMAIII or arsenite can block the use of
selenite for selenoprotein synthesis when cells
are cultured in deﬁned medium.
Reporter gene fusion analysis of seleno-
protein synthesis. Using a reporter gene fusion
construct recently described by Handy
(Handy et al. 2005), we assessed readthrough
of the UGA codon [with appropriate seleno-
cysteine insertion sequence (SECIS) element
in the sense conﬁguration] when COS7 cells
were treated with arsenite. This analysis is
limited to serum-containing media, as COS7
cells require serum for growth, but this would
demonstrate the impact of arsenicals when
serum selenium sources are provided. First,
cytotoxicity of arsenite was assessed, and these
results are shown in Figure 8A. Most notably,
no stimulation of metabolic activity was
observed in this cell line (African green mon-
key kidney cells). Low micromolar concentra-
tions (1–3 µM) had little impact on cell
viability, and a 50% reduction in cell viability
was observed upon addition of 20 µM arsen-
ite to the culture medium.
To confirm that the impact of arsenite
would be similar to that seen in other cell
types (HaCat, HeLa, NIH3T3), we treated
COS7 with 2 or 6 µM arsenite in the pres-
ence of radioisotope selenium (Figure 8B).
Arsenite again reduced incorporation of sele-
nium into all selenoproteins in a concentra-
tion-dependent manner. Given these results,
it was clear that arsenite is capable of blocking
the use of selenite as the source of selenium in
COS7 cells, even when present at concentra-
tions that are not cytotoxic (as observed in
HaCat and other cell lines).
The hSECIS/S (SECIS element in the
sense orientation) reporter gene fusion was
transfected into COS7 cells, and 3 hr after
transfection (in serum-containing medium),
arsenite was added at a concentration of 4 µM.
Selenium was also added in the form of selenite
to assess whether the readthrough was stimu-
lated by addition of selenite, as previously
reported (Handy et al. 2005). Addition of
selenite alone increased relative luciferase activ-
ity, approximately 30% above that of control
cells (Figure 8C). Treatment with arsenite
alone reduced the readthrough of the UGA
codon. Although this was statistically signiﬁ-
cant (p < 0.05), the level of luciferase activity
decreased only 20%. When selenite and arsen-
ite were both added, readthrough was inhibited
about 20% by addition of 4 µM arsenite; how-
ever, this reduction was not statistically signiﬁ-
cant (Figure 8C). This was consistent with
radioisotope labeling of keratinocytes
(Figure 2A) when assessing incorporation of
selenium from selenite. The basal level of UGA
codon readthrough is likely due to selenium
coming from sources in the serum, which is
consistent with the data presented in Figures 2
and 5 for treatment with arsenite.
To test this possibility, COS7 cells were
transfected in low serum conditions (0.1%)
and treated with arsenite. Cells were condi-
tioned for 24 hr in low-serum medium before
transfection to eliminate residual serum-
derived selenium in the cellular selenium
Impact of arsenicals on selenoprotein synthesis
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Figure 7. Arsenite and MMAIII inhibit new synthesis of TrxR1 and cGpx in defined medium (DKM).
Immunoblot analysis of TrxR1, cGpx, and β-actin from cytosolic extracts of cells treated with arsenite and
MMAIII, as described in Figure 4. 
Control
Arsenite (μM) MMAIII (μM)
TrxR1
cGpx
β-Actin
26 1 3
Figure 8. Arsenite reduces but does not eliminate readthrough of UGA codon in serum-containing medium. To
analyze the cell’s ability to readthrough the UGA codon with the appropriate SECIS element, we used a gene
reporter fusion described by Handy et al. (2005). (A) Cytotoxicity of arsenite in COS7 cells. MTT dye reduction
was assessed after incubating cells with arsenicals for 24 hr, and the absorbance obtained was compared
with untreated cells to determine the relative percent cell viability. Error bars represent mean ± SD for at least
three independent cultures treated with arsenite. (B) Arsenite blocks incorporation of radiolabeled selenium in
COS7 cells. Cells were cultivated in the presence of 75Se-selenite (10 nM) and treated with sodium arsenite at
the concentrations indicated. Cells were harvested after 24-hr incubation, and 20 µg of protein from crude cell
extract was separated by 12% SDS-PAGE. (C) Readthrough of UGA codon is resistant to arsenite. The gene
reporter fusion denoted UGA SECIS/S (Handy et al. 2005) was transfected (250 ng) into COS7 cells cultured in
DMEM with 10% serum. Transfection efficiency was determined by co-transfecting pRL-CMV encoding
Renilla luciferase (Promega). Relative luciferase activity in control cells (no arsenicals) is taken as 100%
readthrough. Selenium and/or arsenite was added to the culture medium before transfection at the concentra-
tions indicated. (D) Readthrough of UGA codon determined in low-serum conditions (0.5% serum). Error bars
represent mean ± SD for at least three independent transfected cultures. 
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Untreated 4 μM As 50 nM Se As/Sepools. Again, arsenite reduced readthrough of
the UGA codon, and this inhibition was
more pronounced with nearly 50% reduc-
tion. Addition of selenite increased read-
through, but arsenite continued to reduce
selenium incorporation (Figure 8D). The
more potent impact of arsenite in low serum
conditions supports the hypothesis that arsen-
ite blocks only selenium derived from selen-
ite, and not that derived from serum.
Arsenite triggers the use of selenium
derived from serum, but not L-selenocysteine.
The cumulative results from radiolabeling,
real-time RT-PCR, and reporter gene fusion
(Figures 2, 5, 6, and 8) strongly suggest that
treatment of cells with arsenite, when serum
is present, stimulates the use of selenium from
serum sources. Selenium is well established to
be present in three forms in serum: seleno-
protein-P, plasma Gpx, and a “small” mol-
ecule form of selenium that has yet to
be characterized (Burk and Hill 2005;
Schomburg et al. 2003). Because the transi-
tioning of HaCat cells from serum-containing
DMEM medium to DKM (with selenite as
the only source of selenium) may have altered
the cell’s response to arsenicals, we tested
whether the addition of serum to DKM
would recover the “inhibitory” effect of arsen-
ite on selenium incorporation. When HaCat
cells were cultured with 10% FBS in DKM,
the response to arsenite mimics the results
observed when cells were cultured with serum
(DMEM; Figure 2). Although we could not
test purified selenoprotein P, we separately
assessed the impact of added L-selenocysteine
to the culture medium in the presence and
absence of arsenite. Surprisingly, the presence
of arsenite in the culture medium still inhib-
ited incorporation of selenium into all seleno-
proteins when “cold” L-selenocysteine was
added instead of serum (Figure 9). Based on
these results alone we cannot determine
which component of serum might be used,
but it is clear that exogenous addition of
L-selenocysteine does not mimic the addition
of serum-derived selenium.
Discussion
There is a growing literature on the metabolic
interactions of arsenic and selenium, yet none
from this perspective. From the results pre-
sented in this report, we have obtained data
that strongly suggest the use of serum-derived
selenium is stimulated in cells in culture upon
addition of arsenite to the culture medium.
The uptake of selenium from serum, regard-
less of the source, is largely unknown. Thus,
studies to determine the uptake of inorganic
selenite versus selenium-derived from seleno-
protein P may benefit from this analysis.
Arsenite also caused an increase in mRNA lev-
els for thioredoxin reductase, whether cultured
in serum-containing media or deﬁned media.
This is likely due to activation of the antioxi-
dant response element (ARE) in the TrxR1
promoter by Nrf2, as has been shown previ-
ously (Pi et al. 2003; Sakurai et al. 2005). It is
clear from the immunoblot analysis that when
serum is present, TrxR levels do increase,
whereas cGpx does not. This is consistent with
changes in the mRNA level. It cannot be ruled
out, however, that the overall pool of selenium
in culture is limiting, and competition
between synthesis of higher levels of TrxR
leads to a decrease in cGpx production.
Evidence presented in this study also
demonstrates that methylated trivalent arseni-
cals have quite profound and different effects
on selenoprotein synthesis compared with the
arsenite. Treatment with MMAIIIstrongly
induced the synthesis of TrxR1, regardless of
the source of selenium. This induction again
may be due to activation by the Nrf2-depen-
dent pathway, yet this is speculative, as no
report in the literature has documented acti-
vation of the Nrf2 pathway using MMAIII.
MMAIII also did not block the use of sele-
nium derived from selenite (assessed by
radioisotope labeling), suggesting strongly
that the addition of a single methyl group to
trivalent arsenic alters the effect of arsenic on
selenium metabolism. This is likely due to the
inability of MMAIII to form a stable deriva-
tive with selenide, as has been shown previ-
ously for arsenite (Gailer et al. 2000, 2002b).
It should be noted that both arsenite (includ-
ing glutathiolated derivatives of arsenite) and
MMAIII are potent inhibitors of enzymes
containing vicinal dithiols (Delnomdedieu
et al. 1993; Lin et al. 1999; Styblo and
Thomas 1995). Clearly, the differential effects
of these closely related arsenicals demonstrate
that the observed changes in selenoprotein
synthesis likely would not be attributed to
binding to a vicinal dithiol.
Cancer cells have been shown to contain
higher levels of TrxR, which is likely to sup-
port elevated needs for deoxyribonucleotide
synthesis during proliferation (Kahlos et al.
2001; Soini et al. 2001). Indeed, several
promising anticancer drugs have now been
shown to target this enzyme with low side
effects attributed to the differential expression
of TrxR in tumors (Hashemy et al. 2006; Lu
et al. 2006). Cells treated with MMAIII dis-
play a reduction in cGpx (at both mRNA and
protein levels) as well as a strong induction of
TrxR. If these changes are found to occur in
other cell types and/or tissues, it likely would
lead to increases in oxidative damage to pro-
tein, lipids and DNA while priming the cell
for uncontrolled growth with higher TrxR
activity. Thus, our results suggest that expo-
sure of cells to MMAIII may be indeed a
recipe for carcinogenesis. Two recent studies
using bladder cell cultures also demonstrated
oxidative stress upon treatment with MMAIII
and arsenite, as well as transformation upon
long-term exposure to MMAIII (Bredfeldt
et al. 2006; Eblin et al. 2006). The impact
that MMAIII has on other cell types, espe-
cially primary cells, with respect to selenopro-
tein synthesis will be the subject of future
studies to determine if this effect is the key to
this highly reactive compound’s carcinogenic
potential.
DMAIII treatment resulted in increased
incorporation of selenium into all seleno-
proteins yet had no effect on speciﬁc stimula-
tion of TrxR1 and also did not block
selenoprotein synthesis. It is not yet known
why addition of a second methyl group would
alter the effect on selenium metabolism, nor is
it clear how administration of DMAIII resulted
in higher levels of selenoprotein synthesis.
Ganyc et al.
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Figure 9. Arsenite treatment induces the use of selenium derived from serum but not from L-seleno-
cysteine (SeCys). HaCat cells were cultivated in DKM as in Figure 5. Where indicated, FBS was added to
10%, or L-selenocystine was added to give 50 nM. Arsenite was added at the concentrations indicated
below the autoradiogram, and cells were allowed to grow for 24 hr, as in the previous experiments shown
in Figures 2 and 5.
026
Arsenite (μM)
TrxR1
cGpx
026 026
DKM DKM + serum DKM + SeCysDMAIII is also less toxic to cells in culture,
likely because of the inability to target the vici-
nal dithiol of lipoic acid–containing enzymes
of the Krebs cycle. It should be noted that a
dimethyldiselenoarsinate anion (Gailer et al.
2002a) has been synthesized in vitro, but has
yet to be identiﬁed in either animal or cell cul-
ture studies. Formation of this compound
could possibly facilitate uptake of selenium,
although this has yet to be tested.
In summary, the results of our study
presented in this article demonstrate that triva-
lent arsenicals can significantly impact the
metabolism of selenium and the expression and
the synthesis of selenoproteins. Pentavalent
arsenicals had negligible effects on seleno-
protein synthesis. Identiﬁcation of the molecu-
lar targets that each of these arsenicals acts upon
within the cell to trigger these responses should
add signiﬁcantly to our understanding of the
carcinogenic potential of arsenic.
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